You don't see a lot of kids with psoriasis, but when you do it can be a big challenge, especially if it's bad and they need a systemic.  The Derms on Drugs are coming to the rescue!  We'll have a special guest - Dr. Doug Kress (who was heavily involved in training all three of the Derms on Drugs) who has enormous experience treating pediatric psoriasis.  We'll get into all the stuff you really need to know:
-What systemic drugs are approved for psoriasis under the age of 18?
-What does the data say about which ones work the best?
-How good is Tremfya, the first IL-23 inhibitor approved in kids, and where will it fit?
-How is psoriasis in kids different from psoriasis in adults?
-What are the roles of the different topicals approved for psoriasis in kids?
-How do we think about therapy selection differently in kids vs adults?
-Do kids get psoriatic arthritis?
-What about shots vs pills in kids?
-How do you talk to parents about the different biologics for kids?
-How do you handle vaccines in kids who are psoriasis biologics?
-Do you ever use methotrexate in kids?

Brought to you by Scholars In Medicine

 The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like: 
 
-Do tattoos protect people against melanoma? 
-What cheap, easy topical works great for fissures in hand eczema? 
-Is Dupixent safe in pregnancy? 
-Are tinted sunscreens actually better than regular mineral sunscreens for melasma? 
-If an alopecia areata patient has failed two or three JAKs, is it worth trying another one? 
-What does the early data show for systemic JAK efficacy in vitiligo? 
-Is there anything better than triamcinolone to inject keloids with? 
-Does some crazy drug Patton found an article about work for hemodialysis associated itch? 
 
So, join us for another episode that'll make you better at what you do while you're having fun listening! 

Join the Derms on Drugs and Dr. Shanthi Narla as we dive into the world of obesity, GLP-1s and dermatology.  Whatever you think about all of these topics, we promise that your patients are hearing about them, reading about them and will be asking about them.  Specifically, we'll get into the latest data about how GLP-1s affect diseases like psoriasis, hidradenitis suppurativa and atopic dermatitis and we'll even touch on if dermatologists should be prescribing GLP-1s.  So, while there aren't any definite answers out there yet, tune in this week and you'll be ready when these hot topics come up!

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:
-When is the best time to start niacinamide for skin cancer prevention?
-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?
-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?
-What can do when for PLEVA that's not responding to the usual treatments?
-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?
-What can you do for patients with skin involvement of systemic mastocytosis?
-Are there patients who really have both atopic dermatitis AND psoriasis?
-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:
-When is the best time to start niacinamide for skin cancer prevention?
-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?
-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?
-What can do when for PLEVA that's not responding to the usual treatments?
-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?
-What can you do for patients with skin involvement of systemic mastocytosis?
-Are there patients who really have both atopic dermatitis AND psoriasis?
-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.

NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.

In this episode, we tackle:
-What network meta-analyses actually measure and how they're conducted
-Why two NMAs can reach opposite conclusions about drug effectiveness
-Red flags to watch for when evaluating NMA quality and reliability
-Practical guidance for incorporating NMA findings into clinical practice

Perfect for dermatology providers, researchers, and pharma professionals who want to critically evaluate the evidence behind treatment guidelines. Tune in for expert analysis that might surprise you about this increasingly common research methodology.

Listen now to become a smarter consumer of dermatology research! 

And be sure to discover more at Scholars In Medicine!

Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers.

We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.

But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?

Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!

Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above.  Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!
So join us for a deep dive into CSU, and yes, there will be trivia at the end!

Visit the ⁠Scholars In Medicine⁠ website for more.

Get ahead of the curve with Derms on Drugs as we break down the most exciting new dermatology research! This week features game-changing studies including an oral probiotic with stunning results for atopic dermatitis, JAK inhibitors for bullous pemphigoid, and IL-23 inhibitors tackling guttate psoriasis.

Plus, we dive deep into:

• Dermoscopy advances for managing longitudinal melanonychia

• If failing an IL-13 inhibitor affects the chances of doing well on another IL-13 inhibitor

• New data on IL-13 inhibitor induced conjunctivitis

• Red light PDT efficacy for superficial basal cell carcinoma

• Early systemic PDE4 inhibition strategies in psoriasis

• Follicular event insights from tapinarof studies

• PDE4 inhibition potential for vitiligo treatment

Perfect for dermatology providers who want cutting-edge clinical pearls they can apply immediately. Tune in for evidence-based insights, practical takeaways, and the signature Derms on Drugs commentary that keeps you engaged while staying current.

See more at ScholarsInMedicine.com

Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.

We cover:

• Can moisturizing infants prevent atopic dermatitis?
• New sunscreen ingredients headed for the US market
• Insights from lichenoid eruptions linked to immune checkpoint inhibitors
• What to do if oral JAKs fail in alopecia areata
• Does CeraVe outperform other moisturizers?
• The real risk of cardiovascular and thromboembolic events with JAK inhibitors
• Why IL-13 inhibitors differ in likelihood of causing arthralgias
• Advances in autologous skin cell transplantation for vitiligo
• The safety of patients self-injecting triamcinolone for acne
• New findings on hypersensitivity reactions after sentinel lymph node biopsy
• Can patch testing help with burning mouth syndrome?
• A drug that reduces cardiovascular mortality in hidradenitis suppurativa
• Novel approaches for chronic erythema nodosum, frontal fibrosing alopecia, and cheilitis granulomatosis
  

Join us for concise, actionable updates and real-world pearls you can apply in clinic today. Whether you’re managing complex cases or keeping up with the literature, this is one episode you don’t want to miss.
Listen now and stay ahead in dermatology!